Idiopathic Pulmonary Fibrosis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Idiopathic Pulmonary Fibrosis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL]) | Phase 2 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-03-27 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisNCT06003426Number of participants that experience spontaneous syncopal events | Phase 3 | Active, not recruiting | 2026-10-06 | in 47 d | 2026-03-24 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFNCT07194382Change from baseline in the morning pre-dose forced vital capacity at Week 12 | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-08-10 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CPIX | Cumberland Pharmaceuticals | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT05571059Change from baseline in Forced Vital Capacity (FVC) in mL | Phase 2 | Recruiting | Jan 2027 | ≤ 164 d | 2026-03-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Idiopathic Pulmonary Fibrosis
most recently updated first53 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics | $335M | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisNCT07284459Absolute change in forced vital capacity (FVC) (mL) | Phase 2 | Recruiting | Drug: PIPE-791 Dose A, PIPE-791 Dose B, Placebo | Idiopathic Pulmonary Fibrosis | 324 | 2026-01-08 | May 2028 | ≤ 650 d | 2026-08-19 |
| TVRD | Tvardi Therapeutics, Incorporated | $25M | Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisNCT05671835Number of Participants with an Adverse Event (AE) | Phase 2 | Completed | Drug: TTI-101, Placebo | Idiopathic Pulmonary Fibrosis | 100 | 2023-05-15 | 2025-08-14actual | — | 2026-08-13 |
| RNTX | Rein Therapeutics | $66M | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisNCT06968845Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs) | Phase 2 | Recruiting | Drug: LTI-03, Placebo · Device: Dry Powder Inhaler | Idiopathic Pulmonary Fibrosis (IPF) | 120 | 2026-02-02 | 2027-09-30 | in 406 d | 2026-08-13 |
| AVLN | Avalyn Pharma Inc. | $1.7B | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFNCT07194382Change from baseline in the morning pre-dose forced vital capacity at Week 12 | Phase 2 | Recruiting | Drug: AP02, Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 160 | 2026-03-10 | Dec 2026 | ≤ 133 d | 2026-08-10 |
| AVLN | Avalyn Pharma Inc. | $1.7B | An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)NCT06951217To evaluate the long-term safety and tolerability outcomes of subjects receiving Avalyn nebulized antifibrotic medications (AP01). | Phase 2 | Recruiting | Combination product: AP01 | Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | 340 | 2025-04-17 | 2031-12-31 | in 1,959 d | 2026-08-07 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary FibrosisNCT05537025results2026-08-05Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Completed | Drug: ARO-MMP7 Inhalation Solution, Placebo | Idiopathic Pulmonary Fibrosis | 105 | 2023-01-30 | 2025-09-05actual | — | 2026-08-05 |
| PLRX | Pliant Therapeutics, Inc. | $71M | Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisNCT06097260results2026-08-05Change From Baseline in Forced Vital Capacity at Week 52 | Phase 2 | Terminatedsponsor's stated reason: DSMB recommendation | Drug: PLN-74809, Placebo | Idiopathic Pulmonary Fibrosis | 320 | 2023-11-16 | 2025-04-04actual | — | 2026-08-05 |
| TRVI | Trevi Therapeutics | $2.7B | NAL ER IPF Respiratory Function and Safety StudyNCT07036029Respiratory Function and Safety Assessed by Number of Participants With Increase in End Tidal Partial Pressure of Carbon Dioxide by Capnography (PetCO2) of at Least 10 Millimetres of Mercury (mmHg) From Baseline, or PetCO2>55 mmHg, for at Least 1 Minute | Phase 1 | Completed | Drug: NAL ER, Placebo | Idiopathic Pulmonary Fibrosis | 9 | 2025-08-21 | 2026-06-30actual | — | 2026-08-03 |
| UTHR | United Therapeutics | $22.2B | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseNCT04905693Long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPF | Phase 3 | Enrolling by invitation | Drug: Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis | 1,850 | 2022-09-06 | Dec 2029 | ≤ 1,229 d | 2026-07-28 |
| MNKD | Mannkind Corporation | $1.3B | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisNCT07679893Safety and Efficacy | Phase 2 | Recruiting | Drug: Nintedanib Dry Powder Inhalation, Placebo | Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | 210 | 2026-06-30 | 2028-01-30 | in 528 d | 2026-07-24 |
| BMY | Bristol-Myers Squibb | $134.9B | Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNCT07722507observationalParticipant reported decision-making process for antifibrotic therapy persistence or discontinuation when considering the impact of tolerability and adverse events collected via semi-structured qualitative participant interviews | — | Not yet recruiting | Drug: Antifibrotic therapy | Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | 40 | 2026-08-01 | 2027-05-31 | in 284 d | 2026-07-23 |
| MNKD | Mannkind Corporation | $1.3B | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary FibrosisNCT07344558(Cohort 1) Events of Bronchospasm | Phase 1 | Completed | Drug: MNKD-201(Nintedanib DPI), Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 27 | 2025-12-22 | 2026-06-17actual | — | 2026-07-22 |
| TRVI | Trevi Therapeutics | $2.7B | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsNCT07671911Relative Change from Baseline in 24-hour Cough Frequency at Week 26 | Phase 3 | Recruiting | Drug: NAL ER, Placebo | Idiopathic Pulmonary Fibrosis | 306 | 2026-06-29 | Jun 2028 | ≤ 680 d | 2026-07-10 |
| TRVI | Trevi Therapeutics | $2.7B | Cough Reduction in IPF With Nalbuphine ERNCT05964335results2026-06-26Relative Change From Baseline in 24-hour Cough Frequency at Week 6 | Phase 2 | Completed | Drug: NAL ER, Placebo, NAL ER, NAL ER | Idiopathic Pulmonary Fibrosis | 165 | 2024-02-06 | 2025-04-24actual | — | 2026-06-26 |
| AZN | AstraZeneca | — | A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.NCT07652658To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24 | Phase 2 | Recruiting | Other: Placebo for AZD8965 · Drug: AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose | Idiopathic Pulmonary Fibrosis (IPF) | 359 | 2026-06-11 | 2028-09-14 | in 756 d | 2026-06-25 |
| UTHR | United Therapeutics | $22.2B | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisNCT04708782Change in Absolute FVC from Baseline to Week 52 | Phase 3 | Completed | Drug: Placebo, Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 598 | 2021-06-01 | 2026-02-02actual | — | 2026-05-05 |
| ABBV | AbbVie | $457.5B | Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary FibrosisNCT07230288Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL) | Phase 2 | Recruiting | Drug: ABBV-142, Placebo for ABBV-142 | Idiopathic Pulmonary Fibrosis | 165 | 2026-01-23 | Sep 2029 | ≤ 1,137 d | 2026-04-09 |
| SNDX | Syndax Pharmaceuticals | $1.8B | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL]) | Phase 2 | Active, not recruiting | Drug: Axatilimab · Other: Placebo | Idiopathic Pulmonary Fibrosis | 145 | 2023-12-11 | Sep 2026 | ≤ 41 d | 2026-03-27 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisNCT06003426Number of participants that experience spontaneous syncopal events | Phase 3 | Active, not recruiting | Drug: BMS-986278, BMS-986278 Placebo | Idiopathic Pulmonary Fibrosis | 1,255 | 2023-09-14 | 2026-10-06 | in 47 d | 2026-03-24 |
| CPIX | Cumberland Pharmaceuticals | $114M | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT05571059Change from baseline in Forced Vital Capacity (FVC) in mL | Phase 2 | Recruiting | Drug: Ifetroban Sodium, Placebo | Idiopathic Pulmonary Fibrosis | 128 | 2024-01-31 | Jan 2027 | ≤ 164 d | 2026-03-05 |
| MNOV | MediciNova | $66M | Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisNCT02503657results2026-01-23Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks | Phase 2 | Completed | Drug: MN-001, Placebo | Idiopathic Pulmonary Fibrosis, IPF | 15 | 2016-03-09 | 2020-12-07actual | — | 2026-01-23 |
| PLRX | Pliant Therapeutics, Inc. | $71M | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)NCT05621252results2025-09-24Primary Outcome | Phase 2 | Completed | Drug: PLN-74809, Placebo | Idiopathic Pulmonary Fibrosis | 10 | 2022-07-13 | 2023-12-27actual | — | 2025-12-05 |
| AMGN | Amgen | $229.9B | A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary FibrosisNCT05032066results2025-12-03Core Phase: Change in FVC % Predicted From Baseline to Week 52 | Phase 2 | Terminatedsponsor's stated reason: The trial was terminated due to not meeting primary or key secondary endpoints. | Drug: HZN-825, Placebo | Idiopathic Pulmonary Fibrosis | 153 | 2022-01-20 | 2024-07-22actual | — | 2025-12-03 |
| UTHR | United Therapeutics | $22.2B | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisNCT05255991Change in Absolute FVC from Baseline to Week 52 | Phase 3 | Completed | Drug: Placebo, Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 597 | 2022-10-04 | 2025-06-30actual | — | 2025-08-15 |
| CTNM | Contineum Therapeutics | $335M | PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPFNCT06683612LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan. | Phase 1 | Completed | Drug: PIPE-791 | Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Progressive, Multiple Sclerosis, Secondary Progressive, Healthy, Healthy Volunteers | 16 | 2024-12-09 | 2025-06-04actual | — | 2025-08-06 |
| RNTX | Rein Therapeutics | $66M | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) PatientsNCT05954988results2025-07-31Incidence of Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Completed | Drug: LTI-03, Placebo | Idiopathic Pulmonary Fibrosis | 24 | 2023-07-06 | 2024-09-25actual | — | 2025-07-31 |
| BIIB | Biogen | $31.4B | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATNCT02036970results2021-07-23Change From Baseline Though Week 16 in 6-Minute Walk Distance (6MWD) for Bardoxolone Methyl Compared to Placebo | Phase 2 | Completed | Drug: Bardoxolone methyl, Placebo | Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis | 166 | 2014-05-31 | 2018-01-19actual | — | 2025-06-10 |
| TRVI | Trevi Therapeutics | $2.7B | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughNCT04030026results2025-05-29Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: NAL ER, Placebo | Idiopathic Pulmonary Fibrosis | 42 | 2019-10-29 | 2022-05-27actual | — | 2025-05-29 |
| KYNB | Kyntra Bio | $28M | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT03955146results2024-09-19DB Period (Main Study Cohort): Change From Baseline in FVC at Week 48 | Phase 3 | Terminatedsponsor's stated reason: Study did not meet its primary endpoint. | Drug: Pamrevlumab, Placebo | Idiopathic Pulmonary Fibrosis | 393 | 2019-06-18 | 2023-03-20actual | — | 2024-09-19 |
| KYNB | Kyntra Bio | $28M | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT04419558results2024-08-12DB Period: Change From Baseline in FVC at Week 48 | Phase 3 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Pamrevlumab, Placebo | Idiopathic Pulmonary Fibrosis | 372 | 2020-09-30 | 2023-09-04actual | — | 2024-08-12 |
| PLRX | Pliant Therapeutics, Inc. | $71M | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisNCT04396756results2024-04-30Part A - Number of Participants With Treatment-Emergent Adverse Events | Phase 2 | Completed | Drug: PLN-74809, Placebo | Idiopathic Pulmonary Fibrosis | 120 | 2020-03-03 | 2023-02-01actual | — | 2024-06-03 |
| AZN | AstraZeneca | — | Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy ParticipantsNCT05134727Part 1: Number of participants with adverse events (AEs) | Phase 1 | Completed | Drug: AZD5055, Placebo | Idiopathic Pulmonary Fibrosis | 63 | 2021-11-18 | 2023-03-31actual | — | 2024-05-16 |
| PLRX | Pliant Therapeutics, Inc. | $71M | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/NCT04072315results2023-12-12Number of Participants With a Predicted Effect on αVβ6 PET ( Positron Emission Tomography) in Lungs After Administration of Drug. | Phase 2 | Completed | Drug: PLN-74809 · Radiation: Knottin tracer | Idiopathic Pulmonary Fibrosis | 9 | 2020-02-13 | 2022-06-27actual | — | 2023-12-12 |
| 6988.T | Nitto Denko Corporation | $14.8B | JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPFNCT03538301results2023-12-11Number of Participants Discontinuing Study Treatment Due to TEAEs | Phase 2 | Completed | Drug: ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose) · Other: Other: Placebo | Idiopathic Pulmonary Fibrosis | 123 | 2018-06-18 | 2022-08-24actual | — | 2023-12-11 |
| 3402.T | Toray Industries, Inc | $12.6B | Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary FibrosisNCT03727802results2023-10-23Incidence and Severity of Adverse Events | Phase 1 | Completed | Drug: TRK-250, Placebo | Idiopathic Pulmonary Fibrosis | 34 | 2018-11-28 | 2022-04-01actual | — | 2023-10-23 |
| KYNB | Kyntra Bio | $28M | Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary FibrosisNCT00074698Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Completed | Drug: FG-3019 | Idiopathic Pulmonary Fibrosis | 21 | 2003-12-08 | — | — | 2023-07-12 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327NCT04069143Incidence of adverse events (AEs) | Phase 1 | Completed | Diagnostic test: 18F-BMS-986327 | Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF) | 14 | 2019-10-01 | 2022-07-12actual | — | 2023-03-07 |
| SNY | Sanofi | — | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary FibrosisNCT02345070results2020-05-26Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52 | Phase 2 | Completed | Drug: SAR156597, placebo | Idiopathic Pulmonary Fibrosis | 327 | 2015-05-01 | 2017-05-22actual | — | 2022-03-24 |
| RNTX | Rein Therapeutics | $66M | Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult SubjectsNCT04233814Incidence of Treatment-Emergent Adverse Events (TEAE) | Phase 1 | Completed | Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03), Placebo | Idiopathic Pulmonary Fibrosis | 71 | 2020-01-20 | 2021-12-23actual | — | 2022-03-07 |
| TBPH | Theravance Biopharma | $880M | TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary FibrosisNCT04589260Part A (SAD) - Adverse Events | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has decided to stop the study due to business reasons. Study was terminated before initiation of part C and D (Decision to not proceed with Parts C and D was not for safety reasons and do not impact the overall risk benefit of the IMP.) | Drug: TD-1058, Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 72 | 2020-10-15 | 2021-05-06actual | — | 2022-02-23 |
| BIIB | Biogen | $31.4B | An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary FibrosisNCT03573505results2020-11-20Change From Baseline in Forced (Expiratory) Vital Capacity (FVC) at Week 52 | Phase 2 | Terminatedsponsor's stated reason: Study was stopped because of safety concerns. | Drug: BG00011, Placebo | Idiopathic Pulmonary Fibrosis | 109 | 2018-09-24 | 2019-11-14actual | — | 2020-12-11 |
| KYNB | Kyntra Bio | $28M | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT01890265results2020-09-04Change From Baseline in FVC (Percent of Predicted FVC Value [% Predicted]) to Week 48 | Phase 2 | Completed | Drug: Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib | Idiopathic Pulmonary Fibrosis | 160 | 2013-07-30 | 2017-11-16actual | — | 2020-09-04 |
| BMY | Bristol-Myers Squibb | $134.9B | Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisNCT01766817results2019-05-22Change From Baseline in Forced Vital Capacity (FVC) Rate to Week 26 | Phase 2 | Completed | Drug: BMS-986020, Placebo matching with BMS-986020 | Idiopathic Pulmonary Fibrosis | 325 | 2013-01-31 | 2016-02-29actual | — | 2020-08-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsNCT03981094Maximum observed serum concentration (Cmax) of BMS-986278 and pirfenidone alone or in combination | Phase 1 | Completed | Drug: BMS-986278, Pirfenidone | Idiopathic Pulmonary Fibrosis (IPF) | 22 | 2019-05-10 | 2019-07-27actual | — | 2020-05-15 |
| BIIB | Biogen | $31.4B | STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT01371305results2020-02-28Number of Participants With Adverse Events (AEs) | Phase 2 | Completed | Drug: BG00011, Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 41 | 2012-07-16 | 2017-03-31actual | — | 2020-02-28 |
| KYNB | Kyntra Bio | $28M | Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary FibrosisNCT01262001To determine the safety and tolerability of FG-3019 administered at doses of 15 mg/kg (Cohort 1 and Cohort 1-EX) and 30 mg/kg (Cohort 2 and Cohort 2-EX) every 3 wks for 45 weeks, and every 3 weeks thereafter for three additional treatment years. | Phase 2 | Completed | Drug: FG-3019, FG-3019 | Idiopathic Pulmonary Fibrosis | 90 | Mar 2011 | 2014-06-26actual | — | 2019-10-09 |
| GILD | Gilead Sciences | $177.9B | Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)NCT01769196results2017-04-13Progression Free Survival | Phase 2 | Terminatedsponsor's stated reason: The Study was terminated due to lack of efficacy. | Drug: Simtuzumab, Simtuzumab placebo | Idiopathic Pulmonary Fibrosis | 544 | 2013-01-31 | 2016-02-23actual | — | 2017-05-30 |
| GILD | Gilead Sciences | $177.9B | Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)NCT01759511results2017-04-04Overall Safety Profile of Simtuzumab | Phase 2 | Terminatedsponsor's stated reason: The Study was terminated due to lack of efficacy. | Drug: Simtuzumab | Idiopathic Pulmonary Fibrosis | 34 | 2012-10-18 | 2016-02-19actual | — | 2017-04-04 |
| AZN | AstraZeneca | — | D2212C00002 J-Phase II StudyNCT02036580results2017-02-23Safety and Tolerability Primarily Assessed by the Number of Patients With Adverse Events | Phase 2 | Completed | Biological: tralokinumab cohort 1, tralokinumab cohort 2 · Other: Placebo | Idiopathic Pulmonary Fibrosis | 37 | Jan 2014 | Nov 2015actual | — | 2017-02-23 |
| SNY | Sanofi | — | To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT01529853Safety/tolerability: Number of participants with Adverse events | Phase 1/2 | Completed | Drug: SAR156597, Placebo (for SAR156597) | Idiopathic Pulmonary Fibrosis | 24 | Jan 2012 | Oct 2013actual | — | 2016-02-15 |
| GILD | Gilead Sciences | $177.9B | A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary FibrosisNCT01362231To characterize the safety, tolerability, and pharmacokinetics (PK) of GS-6624 | Phase 1 | Completed | Drug: GS-6624 | Idiopathic Pulmonary Fibrosis | 48 | Dec 2010 | Dec 2012actual | — | 2015-07-09 |
| GILD | Gilead Sciences | $177.9B | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisNCT00879229results2014-04-22Change From Baseline in Six-minute Walk Distance (6MWD). | Phase 3 | Terminated | Drug: Ambrisentan, Placebo | Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension | 40 | Jul 2009 | Feb 2011actual | — | 2014-05-15 |
| GILD | Gilead Sciences | $177.9B | (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPFNCT00768300results2014-04-08Time to Death or Disease (IPF) Progression. | Phase 3 | Terminatedsponsor's stated reason: Lack of efficacy | Drug: Ambrisentan, Placebo | Idiopathic Pulmonary Fibrosis | 494 | Dec 2008 | Feb 2011actual | — | 2014-04-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Idiopathic Pulmonary Fibrosis is matched — 2 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Idiopathic Pulmonary Fibrosis” (a text search, wider than this page)